We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Eco Animal Health Group Plc | LSE:EAH | London | Ordinary Share | GB0032036807 | ORD 5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 5.00 | 4.88% | 107.50 | 82,748 | 16:04:12 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 105.00 | 110.00 | 107.50 | 102.50 | 102.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Chem,fertlizer Minrl Mng,nec | 85.31M | 1.01M | 0.0149 | 72.15 | 72.83M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:38:04 | O | 3,000 | 105.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 25/4/2024 | 16:00 | ALNC |  EARNINGS AND TRADING: ECO Animal revenue up; Zephyr starts drilling |
| 25/4/2024 | 07:00 | UK RNS | Eco Animal Health Group PLC Trading Update on year ended 31 March 2024 |
| 08/4/2024 | 07:00 | UK RNS | Eco Animal Health Group PLC Holding(s) in Company |
| 04/4/2024 | 14:04 | ALNC | ECO Animal Health streamlines product portfolio with disposal |
| 04/4/2024 | 07:00 | UK RNS | Eco Animal Health Group PLC Disposal of non-core product line |
| 22/3/2024 | 07:00 | UK RNS | Eco Animal Health Group PLC Share Awards to Executive Directors |
| 21/3/2024 | 19:05 | ALNC | EARNINGS AND TRADING: Getech confident; Aukett Swanke makes buy |
| 21/3/2024 | 09:13 | UK RNS | Eco Animal Health Group PLC Replacement: Trading Update |
| 21/3/2024 | 07:00 | UK RNS | Eco Animal Health Group PLC Trading Update |
| 19/3/2024 | 09:40 | UK RNS | Eco Animal Health Group PLC General Meeting Result |
Eco Animal Health (EAH) Share Charts1 Year Eco Animal Health Chart |
|
1 Month Eco Animal Health Chart |
Intraday Eco Animal Health Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 25/4/2024 | 08:34 | Eco Animal Health Group: Early dewormer gets OK | 1,547 |
| 05/4/2024 | 10:45 | Eco Animal Health | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-04-26 15:38:06 | 105.00 | 3,000 | 3,150.00 | O |
| 2024-04-26 15:18:38 | 109.60 | 2,500 | 2,740.00 | O |
| 2024-04-26 15:04:12 | 108.00 | 3,150 | 3,402.00 | O |
| 2024-04-26 14:57:29 | 108.00 | 3,600 | 3,888.00 | O |
| 2024-04-26 14:26:38 | 105.66 | 490 | 517.73 | O |
| Top Posts |
|---|
Posted at 26/4/2024 09:20 by Eco Animal Health Daily Update Eco Animal Health Group Plc is listed in the Chem,fertlizer Minrl Mng,nec sector of the London Stock Exchange with ticker EAH. The last closing price for Eco Animal Health was 102.50p.Eco Animal Health currently has 67,744,889 shares in issue. The market capitalisation of Eco Animal Health is £72,825,756. Eco Animal Health has a price to earnings ratio (PE ratio) of 72.15. This morning EAH shares opened at 102.50p |
Posted at 09/4/2024 11:57 by boonkoh Seems to me that Schroders has cleared an overhang which was weighing down on the share price?Nice rise today on small volumes. |
Posted at 07/4/2024 08:03 by cerrito Citywire summarizes the views of Shorequote Vet pharmaceutical group Eco Animal Health (EAH) has potential locked in its pipeline and is driving forward its core business with its latest disposal, says Shore Capital. Analyst Sean Conroy retained his ‘buy’ recommendation and ‘fair value’ target price of 175p on the stock, which softened 0.4% to 84.7p yesterday after the disposal of its non-core ECOmectin Horsepaste product line to its manufacturing partner for €1.3m. Conroy said the disposal shows that the group is focused on ‘driving forwards its core business of treatments and preventatives for pigs and poultry’. Shares in the business are trading on embedded value to pre-tax profit ratio of 5.8 times full-year 2024 and 5.1 times full-year 2024, which Conroy said was a ‘sizeable discount to animal health peers on 12 times and 11 times, respectively’. Sentiment has improved on the back of a positive trading update, but it has further to go if there is to be clarity on performance for the year at the next update. Conroy said there is ‘growth potential’ in the pipeline which means Eco Animal Health should ‘trade closer to the peer group average’. ‘Securing regulatory approvals for its mycoplasma poultry vaccines should provide a catalyst to allow more value to be ascribed to the pipeline,’ he said. ‘However, when discounting the dynamics of the development pipeline from our model, we still value the underlying commercial business at 150p, and, hence, we see a good buying opportunity from both a growth and value perspective.’ Next: SSP enjoying ongoing momentum |
Posted at 04/4/2024 07:28 by edmonda Disposal of non-core equine treatment for €1.3mEco Animal Health has announced the disposal of its treatment for equine parasitic infections, ECOmectin® Horsepaste, to its long-term Italian manufacturing partner ACME Drugs S.r.l. ACME will acquire all ECOmectin® Horsepaste intellectual property, manufacturing and inventory, distribution arrangements and marketing authorisations. The total consideration for the deal is €1.3m (£1.1m), comprising €0.5m paid on signature of the sale and purchase agreement and two further payments of €0.4m payable 18 months and 36 months post-completion, each of which is unconditional and supported with a bank guarantee to be put in place within 45 days. Our Fair Value range is 137p-146p which contrasts with the current share price and suggests that the potential contribution to earnings from the product development pipeline deserves far closer attention. |
Posted at 23/3/2024 14:26 by cerrito I found this on Citywirequote Vet pharmaceutical group Eco Animal Health (EAH) delivered a ‘reassuringly positive’ trading update and is offering both growth and value, says Shore Capital. Analyst Sean Conroy retained his ‘buy’ recommendation and a ‘fair value’ target price of 175p on the stock, which climbed 2.9%, or 2.5p, to 88p yesterday after ‘delivering robust growth in the current environment’ owing to its ‘commercial prowess’. Although the group has not been immune from recent weakness in pork prices it has demonstrated ‘a high degree of resilience to the ongoing lull in the hog cycle’. Conroy said the shares are trading on an embedded value to pre-tax earnings ratio of 5.9 times for 2025 and 5.3 times for 2025, which is a ‘sizeable discount to animal health peers on 12 times and 11 times, respectively’. He said the stock should trade closer to peers, inferring 100% upside to the share price. ‘Securing regulatory approvals for its Mycoplasma poultry vaccines in the first half 2025 should provide a catalyst to allow more value to be ascribed to the pipeline,’ he said. ‘However, when discounting the dynamics of the development pipeline from our model, we still value the underlying commercial business at 150p and hence, we see a good buying opportunity from both a growth and value perspective.’ |
Posted at 21/3/2024 07:28 by edmonda "Sustained demand and continuing progress"For the year ended 31 March 2024, Eco Animal Health reports progress in both the second half and Q4, underpinned by demand for the Group’s proprietary Aivlosin® antibacterial treatment for gastrointestinal and respiratory diseases in pigs and poultry. The Group reports sustained demand for Aivlosin® across the territories it targets, which we note are worldwide: China, Japan and SE Asia, the Americas and Europe. The Group expects FY24 revenue to be in line with a market consensus estimate of £88.7m. Following the November Capital Markets event we reviewed the contribution to valuation of the product development pipeline, particularly in light of the strong track record established by Aivlosin® . Our resulting Fair Value range was 137p - 146p. This contrasts with the current share price, and suggests that the potential contribution to earnings of the product development pipeline deserves far closer attention. Link to research note: |
Posted at 19/3/2024 21:25 by cerrito I am always interested in voter turnout at SGM and AGM of AIM companies to see how engaged shareholders are. Pretty much at EAH as 40m of the 67m shares were voted for routine and noncontroversial motions. |
Posted at 15/3/2024 11:58 by pugugly 1 year breakout DOWN. Skids really under EAH.p/ratio high and PEG too high for my liking. Plus of course political risk in main market. Anyone like to call the bottom? |
Posted at 17/2/2024 17:26 by cerrito I see the price has drifted down in the last few days with both Wednesday and Friday busy by EAH standards.I note last year we had a TU on March 8th and the year before on March 15th and am going on the basis that we will have one in the first half of this March. |
Posted at 28/11/2023 20:31 by cerrito Having a look at the interims before the call tomorrow. You are right Mr Macgregor to point out that they are delphic in their silence on China. Good to read about good cash balances ex China. Good for them for spelling out so clearly where the cash is located and go bing us their understanding of current market consensus.I note that full year revenue forecast of £88m suggests H2 revenue of £50m broadly on a par with H2 22/23.The full year adjusted Ebitda of £7.7m suggests a H2 figure of £7m, compared to £5.6m in H2 22/23.Good if they can do it.I am not a great fan of ebitda, especially if adjusted. I see here that the I is negligible, but I see the d&a was £2.3m in the last FY and £1.2m in H1 of the current FY. The issue is tax, with a 93pc effective tax rate in H1, albeit 32pc in the last financial year.I note that Singers have reconfirmed the target price of 268p. If their R&D efforts pay off perfectly possible they get to this figure but we may well have to wait till calendar 2026 at the very earliest. The 2.5p Share price increase this week seems fair enough and as long as none of the major shareholders lose patience, we should avoid going into double figure territory. On that note since February we have only has 2 TR-1 notices and on both cases it was for an increase in holding(L Odier and Schroders). Inc |
Posted at 09/1/2023 09:10 by cerrito Given the ANP news this morning especially with reference to China was expecting a slight fall here but of course the current EAH share price has alot of bad-even if transitory - news baked in. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
